BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12952566)

  • 1. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
    Yeoh C; Chau I; Cunningham D; Norman AR; Hill M; Ross PJ
    Clin Colorectal Cancer; 2003 Aug; 3(2):102-7. PubMed ID: 12952566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.
    Witte RS; Cnaan A; Mansour EG; Barylak E; Harris JE; Schutt AJ
    Cancer; 2001 Mar; 91(5):1020-8. PubMed ID: 11251955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
    Thirion P; Michiels S; Pignon JP; Buyse M; Braud AC; Carlson RW; O'Connell M; Sargent P; Piedbois P;
    J Clin Oncol; 2004 Sep; 22(18):3766-75. PubMed ID: 15365073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
    J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.
    J Natl Cancer Inst; 1997 Apr; 89(7):497-505. PubMed ID: 9086006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
    Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
    Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer.
    Matsuoka H; Nagaya M; Tsukikawa S; Yanagi Y; Isogai A; Kubota S
    Surgery; 2006 Sep; 140(3):387-95. PubMed ID: 16934600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
    Bensmaïne MA; Marty M; de Gramont A; Brienza S; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Cvitkovic E
    Br J Cancer; 2001 Aug; 85(4):509-17. PubMed ID: 11506488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival of patients with advanced colorectal cancer may not be due to the response to chemotherapy.
    Stathopoulos GP; Rigatos SK; Malamos NA; Stathopoulos JG; Thallasinou P; Papazachariou E; Antoniou F; Kondopodis E; Xynotroulas J
    Oncol Rep; 2004 Dec; 12(6):1295-300. PubMed ID: 15547753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
    Jpn J Clin Oncol; 1995 Jun; 25(3):91-103. PubMed ID: 7596054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
    Maisey N; Chau I; Cunningham D; Norman A; Seymour M; Hickish T; Iveson T; O'Brien M; Tebbutt N; Harrington A; Hill M
    J Clin Oncol; 2002 Jul; 20(14):3130-6. PubMed ID: 12118027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Lonardi S; Bandelloni R; Casazza S; Monfardini S; Gallo L
    J Clin Oncol; 2004 Sep; 22(18):3758-65. PubMed ID: 15365072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
    Price TJ; Ross PJ; Hickish T; Tait D; Norman AR; Ford HE; Middleton G; Sumpter K; Hill M; Oates J; Cunningham D
    Clin Colorectal Cancer; 2004 Feb; 3(4):235-42. PubMed ID: 15025796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
    Tebbutt NC; Norman A; Cunningham D; Iveson T; Seymour M; Hickish T; Harper P; Maisey N; Mochlinski K; Prior Y; Hill M
    Ann Oncol; 2002 Oct; 13(10):1568-75. PubMed ID: 12377644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
    Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
    Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.